Panelists discuss how dermatologists should expand their therapeutic scope beyond traditional steroids and calcineurin inhibitors to embrace newer nonsteroidal options, while emphasizing that treating pediatric atopic dermatitis requires the same principles as adult care and encouraging broader provider participation, including pediatricians, to address access challenges.
Panelists discuss how future therapies should aim to provide faster symptom relief than the current 4- to 8-week timeframe, offer longer-lasting depot effects requiring less frequent application, and accelerate the regulatory process for extending safe adult medications to younger pediatric populations.
At Elevate-Derm Fall, Ken Korber, PA-C, MHPE, DFAAPA, highlighted how literacy-aware communication and team-based collaboration can elevate patient understanding, adherence, and outcomes.
Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.
At Elevate-Derm Fall, Ted Rosen, MD, detailed how rapidly evolving resistance in bacteria, fungi, viruses, and more is reshaping therapeutic choices.
Clinicians can enhance aesthetic outcomes by proactively managing GLP-1 patients' expectations, addressing facial changes early, and integrating holistic treatment strategies.
Hilary Baldwin, MD, introduces the series and reviews acne pathogenesis, mechanisms of topical therapies, and key barriers to adherence in everyday practice.
Panelists discuss how switching from biologics to JAK inhibitors offers rapid, meaningful improvement and restores disease control for patients with persistent atopic dermatitis.
At Elevate-Derm 2025, Diego Ruiz Dasilva, MD, emphasized cross-role teamwork and urged clinicians to consider positive JAK inhibitor safety data.
A panelist discusses how evolving safety evidence and real-world considerations will shape clinician confidence and best practices for oral systemic therapies.
Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy, according to Michael Lewitt, MD.
GLP-1 medications are reshaping dermatology, driving increased patient demand for treatments addressing facial volume loss and jowling concerns, according to Joely Kaufman, MD.
Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.
At Elevate-Derm, Buchi Neita, PA-C, discussed treatment expectations for vitiligo, triple-combination cream for acne, early diagnosis in HS, and what she’s looking forward to in the 2026 pipeline.
At Elevate-Derm Fall, Patricia Delgado, DNP, AGPCNP, DCNP, PMHNP, outlined practical ways dermatology clinicians can incorporate psychodermatology principles and previewed the upcoming Psych and Skin video series.
Lisa Weiss, MMSc, PA-C, and Justin Love, PA-C, discuss the importance of broad differentials, repeat biopsies, and national networking to strengthen diagnostic accuracy and provider support at Elevate-Derm Fall.
At Elevate-Derm Fall, Peter Lio, MD, discussed how flexible clinical reasoning and an expanding therapeutic pipeline, particularly hidradenitis suppurativa and atopic dermatitis, are reshaping patient management heading into 2026.
At Elevate-Derm Fall, sisters Shanna Miranti, MPAS, PA-C, and Larissa Schmidt, DPM, reviewed the benefits of cross-specialty collaboration for patient care.
At the Elevate-Derm Fall Conference, Peter Lio, MD, highlighted practical strategies for corticosteroid stewardship, the expanding role of nonsteroidal topicals, and emerging opportunities in early-age indications that are reshaping pediatric inflammatory dermatoses care.
Chronic itching can reflect systemic disease, highlighting the importance of comprehensive assessment.
Panelists discuss how comprehensive caregiver education forms the foundation of successful treatment, involving dispelling internet misinformation, demonstrating proper application techniques like fingertip units, addressing steroid fears, and establishing realistic expectations about long-term management rather than seeking quick cures.
Panelists discuss how they determine when to escalate to systemic therapies by focusing on patient-reported outcomes rather than clinical appearance alone, asking about flare frequency and typical vs bad days, while emphasizing the importance of continuing topicals alongside systemics with potential for future de-escalation.
At Elevate-Derm Fall, Victoria Garcia-Albea, NP, details the expanding educational landscape in hair disease management, the rise of dedicated hair health meetings, and practical pathways for clinicians looking to advance professionally through writing.
Victoria Garcia-Albea, NP, outlined evolving therapeutic strategies at Elevate-Derm Fall, highlighting low-dose oral minoxidil, off-label JAK inhibition for frontal fibrosing alopecia, Thiamidol in hyperpigmentation, and delgocitinib for chronic hand eczema.
Kim explores the significance of inflammation in dermatology, revealing its connections to various diseases and the importance of focused research.
Hilary Baldwin, MD, introduces the series and reviews acne pathogenesis, mechanisms of topical therapies, and key barriers to adherence in everyday practice.
Marc Serota, MD, discussed upcoming systemic JAK inhibitors, the value of ruxolitinib cream and phototherapy, and a personalized multimodal approach to improve repigmentation outcomes.
A panelist discusses how mechanistic insights and head-to-head data are reshaping systemic therapy development, trial design, and personalized treatment strategies.
Marc Serota, MD, outlines how ruxolitinib cream supports gradual, sustained repigmentation, highlights the significance of “islands” of early pigment return, and discusses when to escalate or combine modalities to optimize outcomes.
Shannon Trotter, DO, and Renata Block, DMSc, MMS, PA-C, discuss social media's impact on dermatology, highlighting trends, misinformation, and the need for clinician engagement.
